28301284|t|Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70
28301284|a|This study aimed to evaluate the immunogenicity and protective efficacy of recombinant bacille calmette-guerin (rBCG) strains expressing Ag85A (A), CFP10 (C), ESAT6 (E), IL-12p70 (I), and fusion protein GM-CSF (G). rBCGs were established by integrating of A, C, E, I, G, AE, CE, IE, GC, GE and GCE into Mycobacterium bovis BCG-1173 and BCG-SH. The macro- effects of rBCGs on mice were evaluated by phenotype and weight. The immunogenicity of rBCGs was analyzed by lgG, lgG1 and lgG2a antibody titers, and IFN-γ and IL-4 contents through Enzyme-linked immunosorbent assay (ELISA). Meanwhile, the proportions of CD4(+) and CD8(+) T splenic lymphocytes were determined using flow cytometry. The protective efficacy of rBCGs was evaluated by bacterial load in spleen and lung tissues from immunized mice. rBCGs exhibited no obvious side effects on mice. The antibody titers of lgG, lgG1 and lgG2a, proportion of CD4(+) and CD8(+) T cells, and concentrations of IFN-γ were found to be significantly higher in multiple - gene rBCGs than that in single-gene rBCGs (P < 0.05). Bacterial load in both spleen and lung tissues from mice infected with M. tuberculosis H37Rv were significantly reduced by rBCGs. A significantly lower bacterial load was revealed in rBCG -1173:A compared with multiple - gene rBCGs (P < 0.05). Immunogenicity was better on multiple - gene rBCGs than on single-gene rBCGs, while excellent protective efficacy was exhibited on rBCG-1173:A and BCG-1173.
28301284	0	14	Immunogenicity	T062	UMLS:C4054739
28301284	30	38	efficacy	T062	UMLS:C1707887
28301284	54	77	Bacille Calmette-Guerin	T007	UMLS:C0085957
28301284	97	110	mycobacterium	T007	UMLS:C0026912
28301284	111	119	antigens	T103	UMLS:C0003320
28301284	120	125	Ag85A	T103	UMLS:C0675617
28301284	127	132	CFP10	T103	UMLS:C1506203
28301284	134	140	ESAT-6	T103	UMLS:C1744314
28301284	142	148	GM-CSF	T103	UMLS:C0079460
28301284	153	161	IL-12p70	T103	UMLS:C0123759
28301284	167	172	study	T062	UMLS:C2603343
28301284	182	190	evaluate	T058	UMLS:C0220825
28301284	195	209	immunogenicity	T062	UMLS:C4054739
28301284	225	233	efficacy	T062	UMLS:C1707887
28301284	249	272	bacille calmette-guerin	T007	UMLS:C0085957
28301284	274	278	rBCG	T007	UMLS:C0085957
28301284	299	304	Ag85A	T103	UMLS:C0675617
28301284	306	307	A	T103	UMLS:C0675617
28301284	310	315	CFP10	T103	UMLS:C1506203
28301284	317	318	C	T103	UMLS:C1506203
28301284	321	326	ESAT6	T103	UMLS:C1744314
28301284	328	329	E	T103	UMLS:C1744314
28301284	332	340	IL-12p70	T103	UMLS:C0123759
28301284	342	343	I	T103	UMLS:C0123759
28301284	350	364	fusion protein	T103	UMLS:C0162768
28301284	365	371	GM-CSF	T103	UMLS:C0079460
28301284	373	374	G	T103	UMLS:C0079460
28301284	377	382	rBCGs	T007	UMLS:C0085957
28301284	418	419	A	T103	UMLS:C0675617
28301284	421	422	C	T103	UMLS:C1506203
28301284	424	425	E	T103	UMLS:C1744314
28301284	427	428	I	T103	UMLS:C0123759
28301284	430	431	G	T103	UMLS:C0079460
28301284	433	435	AE	T103	UMLS:C3181051
28301284	437	439	CE	T103	UMLS:C0162768
28301284	441	443	IE	T103	UMLS:C0162768
28301284	445	447	GC	T103	UMLS:C0162768
28301284	449	451	GE	T103	UMLS:C0162768
28301284	456	459	GCE	T103	UMLS:C0162768
28301284	465	493	Mycobacterium bovis BCG-1173	T007	UMLS:C0085957
28301284	498	504	BCG-SH	T007	UMLS:C0085957
28301284	528	533	rBCGs	T007	UMLS:C0085957
28301284	537	541	mice	T204	UMLS:C0025929
28301284	547	556	evaluated	T058	UMLS:C0220825
28301284	586	600	immunogenicity	T062	UMLS:C4054739
28301284	604	609	rBCGs	T007	UMLS:C0085957
28301284	626	629	lgG	T017	UMLS:C2754943
28301284	631	635	lgG1	T017	UMLS:C2754944
28301284	640	654	lgG2a antibody	T017	UMLS:C2754946
28301284	667	672	IFN-γ	T103	UMLS:C0021745
28301284	677	681	IL-4	T103	UMLS:C0021758
28301284	699	732	Enzyme-linked immunosorbent assay	T058	UMLS:C0014441
28301284	734	739	ELISA	T058	UMLS:C0014441
28301284	772	778	CD4(+)	T017	UMLS:C0039215
28301284	783	811	CD8(+) T splenic lymphocytes	T017	UMLS:C0242629
28301284	834	848	flow cytometry	T058	UMLS:C0016263
28301284	865	873	efficacy	T062	UMLS:C1707887
28301284	877	882	rBCGs	T007	UMLS:C0085957
28301284	887	896	evaluated	T058	UMLS:C0220825
28301284	918	924	spleen	T017	UMLS:C0771377
28301284	929	941	lung tissues	T017	UMLS:C0819757
28301284	957	961	mice	T204	UMLS:C0025929
28301284	963	968	rBCGs	T007	UMLS:C0085957
28301284	990	1002	side effects	T038	UMLS:C0879626
28301284	1006	1010	mice	T204	UMLS:C0025929
28301284	1016	1024	antibody	T103	UMLS:C0003241
28301284	1035	1038	lgG	T017	UMLS:C2754943
28301284	1040	1044	lgG1	T017	UMLS:C2754944
28301284	1049	1054	lgG2a	T017	UMLS:C2754946
28301284	1070	1076	CD4(+)	T017	UMLS:C0039215
28301284	1081	1095	CD8(+) T cells	T017	UMLS:C0242629
28301284	1119	1124	IFN-γ	T103	UMLS:C0021745
28301284	1177	1181	gene	T017	UMLS:C0017337
28301284	1182	1187	rBCGs	T007	UMLS:C0085957
28301284	1201	1212	single-gene	T017	UMLS:C0017337
28301284	1213	1218	rBCGs	T007	UMLS:C0085957
28301284	1254	1260	spleen	T017	UMLS:C0771377
28301284	1265	1277	lung tissues	T017	UMLS:C0819757
28301284	1283	1287	mice	T204	UMLS:C0025929
28301284	1288	1296	infected	T033	UMLS:C0439663
28301284	1302	1323	M. tuberculosis H37Rv	T007	UMLS:C1449831
28301284	1354	1359	rBCGs	T007	UMLS:C0085957
28301284	1414	1418	rBCG	T007	UMLS:C0085957
28301284	1452	1456	gene	T017	UMLS:C0017337
28301284	1457	1462	rBCGs	T007	UMLS:C0085957
28301284	1475	1489	Immunogenicity	T062	UMLS:C4054739
28301284	1515	1519	gene	T017	UMLS:C0017337
28301284	1520	1525	rBCGs	T007	UMLS:C0085957
28301284	1534	1545	single-gene	T017	UMLS:C0017337
28301284	1546	1551	rBCGs	T007	UMLS:C0085957
28301284	1580	1588	efficacy	T062	UMLS:C1707887
28301284	1606	1617	rBCG-1173:A	T007	UMLS:C0085957
28301284	1622	1630	BCG-1173	T007	UMLS:C0085957